Abstract
Statement of Purpose: Rheumatoid arthritis (RA) is a chronic, disabling autoimmune condition afflicting about 0.3 – 1% of the world’s adult population[1]. One potential avenue for treatment of RA is the development of RA-specific tolerogenic dendritic cells (tDCs). Tolerogenic DCs (tDCs) are an attractive solution for treatment of RA in that they target the immune cascade responsible for RA, rather than addressing the symptoms as with most convention therapies. Previously, it has been demonstrated that exogenously-treated tDCs can limit autoimmunity in a RA murine model[2]. However, ex-vivo stability and manufacturing cost inhibit the widespread use of exogenously-treated tDCs in autoimmune treatments. In an effort to circumvent drawbacks with exogenously-derived tDC therapy, an “anti-vaccine" (Avac) delivering tolerogenic factors via poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs) that passively target DCs has been explored as a potential system for autoimmune disease treatment[3]. Our working hypothesis is that this Avac will modulate DC phenotype in vivo, thereby modulate downstream T and B cell responses, ultimately suppressing autoimmunity in a collagen-induced arthritis (CIA) murine model.
| Original language | English (US) |
|---|---|
| Title of host publication | Society for Biomaterials Annual Meeting and Exposition 2019 |
| Subtitle of host publication | The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting |
| Publisher | Society for Biomaterials |
| Number of pages | 1 |
| ISBN (Electronic) | 9781510883901 |
| DOIs | |
| State | Published - Jan 1 2019 |
| Event | 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States Duration: Apr 3 2019 → Apr 6 2019 |
Publication series
| Name | Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium |
|---|---|
| Volume | 40 |
| ISSN (Print) | 1526-7547 |
Conference
| Conference | 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence |
|---|---|
| Country | United States |
| City | Seattle |
| Period | 4/3/19 → 4/6/19 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Biotechnology
- Biomaterials
- Materials Chemistry
Cite this
Combinatorial, microparticle-based delivery of immune modulators reprograms dendritic cell phenotype and promotes remission of collagen-induced arthritis in mice. / Allen, Riley; Chizari, Shawn; McKibbin, Luke; Raychaudhuri, Siba P; Lewis, Jamal S.
Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Combinatorial, microparticle-based delivery of immune modulators reprograms dendritic cell phenotype and promotes remission of collagen-induced arthritis in mice
AU - Allen, Riley
AU - Chizari, Shawn
AU - McKibbin, Luke
AU - Raychaudhuri, Siba P
AU - Lewis, Jamal S.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Statement of Purpose: Rheumatoid arthritis (RA) is a chronic, disabling autoimmune condition afflicting about 0.3 – 1% of the world’s adult population[1]. One potential avenue for treatment of RA is the development of RA-specific tolerogenic dendritic cells (tDCs). Tolerogenic DCs (tDCs) are an attractive solution for treatment of RA in that they target the immune cascade responsible for RA, rather than addressing the symptoms as with most convention therapies. Previously, it has been demonstrated that exogenously-treated tDCs can limit autoimmunity in a RA murine model[2]. However, ex-vivo stability and manufacturing cost inhibit the widespread use of exogenously-treated tDCs in autoimmune treatments. In an effort to circumvent drawbacks with exogenously-derived tDC therapy, an “anti-vaccine" (Avac) delivering tolerogenic factors via poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs) that passively target DCs has been explored as a potential system for autoimmune disease treatment[3]. Our working hypothesis is that this Avac will modulate DC phenotype in vivo, thereby modulate downstream T and B cell responses, ultimately suppressing autoimmunity in a collagen-induced arthritis (CIA) murine model.
AB - Statement of Purpose: Rheumatoid arthritis (RA) is a chronic, disabling autoimmune condition afflicting about 0.3 – 1% of the world’s adult population[1]. One potential avenue for treatment of RA is the development of RA-specific tolerogenic dendritic cells (tDCs). Tolerogenic DCs (tDCs) are an attractive solution for treatment of RA in that they target the immune cascade responsible for RA, rather than addressing the symptoms as with most convention therapies. Previously, it has been demonstrated that exogenously-treated tDCs can limit autoimmunity in a RA murine model[2]. However, ex-vivo stability and manufacturing cost inhibit the widespread use of exogenously-treated tDCs in autoimmune treatments. In an effort to circumvent drawbacks with exogenously-derived tDC therapy, an “anti-vaccine" (Avac) delivering tolerogenic factors via poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs) that passively target DCs has been explored as a potential system for autoimmune disease treatment[3]. Our working hypothesis is that this Avac will modulate DC phenotype in vivo, thereby modulate downstream T and B cell responses, ultimately suppressing autoimmunity in a collagen-induced arthritis (CIA) murine model.
UR - http://www.scopus.com/inward/record.url?scp=85065413780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065413780&partnerID=8YFLogxK
U2 - 10.1021/acsabm.9b00092
DO - 10.1021/acsabm.9b00092
M3 - Conference contribution
T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
BT - Society for Biomaterials Annual Meeting and Exposition 2019
PB - Society for Biomaterials
ER -